Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 4, 2020
Daily News
November 4, 2020
- Sosei, Aditum Bio Form New Firm to Develop Neurological Disease Drugs
November 4, 2020
- Ryukaikon Confab Finally Set for November 24; Can Japan Improve Drug Distribution Environment Again?
November 4, 2020
- Working Group Agrees to Designate 10-20 “Stable Supply Medicines” as Top Priority Drugs
November 4, 2020
- Astellas Now Aims at Peak Sales of 300-400 Billion Yen for Padcev with New Indications
November 4, 2020
- Shionogi/Tetra’s Cognitive Disorder Med Delivers Positive PII Data
November 4, 2020
- JCR Can Strike Global Licensing Deal for Lysosomal Therapies at Least by March-End: Chief
November 4, 2020
- Health Minister Stresses Importance of Japan-Made Vaccines Too
November 4, 2020
- Kyowa Kirin’s Overseas Sales Ratio Nears 50%, Driven by Crysvita in Europe, US: January-September
November 4, 2020
- Daiichi Sankyo Promoting Home Use of Inavir to Reduce COVID-19 Risk at Medical Institutions
November 4, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…